

BBS Seminar

Quantitative Benefit-Risk: What Matters to Whom and How? - Getting the Values and Weights Right

Thursday, 21 July 2011

Bildungszentrum 21

Missionsstrasse 21

4003 Basel




1

Benefit-Risk Assessment

- Quantitative vs Qualitative approaches
- Transparency of decision making process
- Reproducibility and consistency of decisions
- Implicit vs explicit assumptions regarding weights and values
- How to cope with subjective decisions and judgments?
- Who's values and weights matter?
- How to elicit and use values and weights in a formalized manner?

Value Tree for BRAT Triptan Example

Full tree with identified and potential outcomes



Source: PhRMA-BRAT

BBS - 21 July 2011

Quantitative Benefit-Risk

3

Scientific Program

John Ferguson (Novartis Vaccines and Diagnostics, USA):

Structured Benefit-Risk Optimization (BRO):

A Framework Quantitative Decision Support Tools

Gordon Francis (Novartis Pharma, USA):

Clinical Perspective on Benefit-Risk Assessments

Lawrence Phillips (The London School of Economics and Political Science, UK):

Quantitative Benefit-Risk: Determining Values & Assessing Weights

Andrea Beyer (University Medical Center Groningen, NL):

Beyond the Probability of Risk: Measuring Perception, Preferences and Values for Health States

BBS - 21 July 2011

Quantitative Benefit-Risk

4